

Active substances set

Search phrase: azacitidine

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Acute myeloid leukemia

Azacitidine

Azacitidine is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: - acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification, - AML with > 30% marrow blasts according to the WHO classification.



**FULL
REIMBURSEMENT**



ESMO